Using a 24-hour continuous glucose monitor after delivery to predict future Type 2 diabetes risk in people with gestational diabetes
Official title: Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial
Run by University of California, Los Angeles · NCT07449039 · Data updated 2026-11-12
This pilot tests whether wearing a continuous glucose monitor for 24 hours immediately after delivery can help predict later Type 2 diabetes risk in people who had gestational diabetes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | University of California, Los Angeles Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Status | Recruiting |
| Started | September 28, 2025 |
| Main results expected | December 2029 |
| Study ends | June 2030 |
| Registry record updated | March 4, 2026 |
| Trial ID | NCT07449039 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18 years) with gestational diabetes who receive prenatal care and plan to deliver at UCLA Ronald Reagan or UCLA Santa Monica and who do not have pre-existing diabetes or other listed exclusions.
✕Probably not a fit
People with pre-gestational diabetes, multifetal pregnancies, certain infections or skin conditions at the sensor site, recent steroid/terbutaline or metformin use, or those not delivering at UCLA are not likely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center pilot enrolls people with a confirmed gestational diabetes diagnosis who receive prenatal care and plan delivery at UCLA. Participants will have a continuous glucose monitor applied within two hours after delivery, wear it for 24 hours, and remove it themselves. Two brief surveys about the device experience and health will be completed at 1–3 months and again at 12–14 months postpartum. The study excludes people with pre-gestational diabetes, multifetal gestation, recent steroid or terbutaline use, certain medical conditions, or planned postpartum imaging, and it is designed to test feasibility and early predictive signal rather than provide diagnosis or treatment.
Why it matters
Potential benefit: If successful, this approach could offer a simple, immediate way to identify people at higher risk of developing Type 2 diabetes so they can get earlier monitoring or prevention efforts.
How similar studies have gone: Continuous glucose monitoring has been used in pregnancy and postpartum settings to detect abnormal glucose patterns, but using immediate postpartum 24-hour CGM specifically to predict long-term Type 2 diabetes risk is a novel, early-stage approach with limited prior evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Prenatal care at UCLA Health * Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica * Confirmed gestational diabetes diagnosis based on 2-step approach * Maternal age \>= 18 years Exclusion Criteria: * Pre-gestational diabetes (T1DM or T2DM) * Multifetal gestation * Intra-amniotic infection by clinical criteria * Postpartum hemorrhage * Maternal ICU admission * Known allergy to medical-grade adhesive * Presence of skin lesions at anticipated CGM application site * Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial * Metformin use * Steroid use * Terbutaline use within 4 hours of delivery * Cystic fibrosis * MODY (mature onset of diabetes in the young)
Where it's running
-
University of California, Los Angeles
Los Angeles, California, United States Recruiting
Study contacts
- Principal investigator: Christina Han, MD — University of California, Los Angeles
- Study coordinator: Rujuta Sathe
- Email: RSathe@mednet.ucla.edu
- Phone: 310-794-8893
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prenatal Exercise to See How Cardio or Strength Training Affects Blood Sugar
This study tests whether different types and amounts of exercise during pregnancy can improve blood sugar control in women with gestational diabetes.
-
Maternal insulin and fat metabolism in pregnancies at risk for preeclampsia and gestational diabetes
This project will try to see if insulin resistance and how the body burns fats early in pregnancy predict later preeclampsia or gestational diabetes in people at higher risk.
-
Behavioral toolkit to help pregnant women manage gestational diabetes and pregnancy-related high blood pressure.
This program will test whether a structured behavioral toolkit helps pregnant women with both gestational diabetes and pregnancy-induced high blood pressure better control their blood sugar and blood pressure.
-
Early pregnancy lifestyle patterns and glucose changes in a TOFFFY sub-study
This study tests whether daily patterns like sleep, activity, and meal timing in early pregnancy affect glucose levels and the risk of gestational diabetes, using CGM and wearable data in pregnant women in Singapore.
-
Continuous glucose monitoring to find and manage early high blood sugar in pregnancy
This uses continuous glucose monitors in early pregnancy for people without diabetes to find and treat high blood sugar and try to reduce problems for mother and baby.
-
Predicting gestational diabetes in early pregnancy using continuous glucose monitoring.
This study is testing if using continuous glucose monitoring in early pregnancy can help identify women at risk for gestational diabetes sooner than usual.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.